Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center
Articles
Fedratinib for Primary Myelofibrosis
Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
July 7th 2020Read More
Ruxolitinib and Surgical Interventions
Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
July 7th 2020Read More
Ruxolitinib for Primary Myelofibrosis
Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
July 7th 2020Read More
Treating Intermediate/High-Risk Primary Myelofibrosis
Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
July 7th 2020Read More
Management of Low-Risk Primary Myelofibrosis
Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
July 7th 2020Read More
Primary Myelofibrosis: Risk Stratification
Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
July 7th 2020Read More
Polycythemia Vera: PROUD-PV Trial
Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
July 7th 2020Read More
Utilization of Ruxolitinib for Polycythemia Vera
Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
July 7th 2020Read More
Polycythemia Vera: Ruxolitinib Trial Data
Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
July 7th 2020Read More
Polycythemia Vera: Switching Therapy
Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
July 7th 2020Read More
Treatment Options for High-Risk Polycythemia Vera
Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
July 7th 2020Read More
Management of Low-Risk Polycythemia Vera
Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
July 7th 2020Read More
Polycythemia Vera: Monitoring Patients
Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
July 7th 2020Read More
Polycythemia Vera: Risk Assessment
Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
July 7th 2020Read More
Polycythemia Vera: Prognostic Markers
Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
July 7th 2020Read More
Polycythemia Vera: Bone Marrow Biopsies
Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
July 7th 2020Read More
Polycythemia Vera: Diagnostic Work-up
Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
July 7th 2020Read More
Characterization of Myeloproliferative Neoplasms
Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
July 7th 2020Read More
Latest Updated Articles
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
